Literature DB >> 9598479

Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?

H G Wiener1, C Mian, A Haitel, A Pycha, G Schatzl, M Marberger.   

Abstract

PURPOSE: We compare the diagnostic value of NMP22 and BTA stat testing, and QUANTICYT computer assisted dual parameter image analysis to cytology and cystoscopy in patients who had symptoms suggestive of transitional cell cancer or were being followed after treatment for that disease.
MATERIALS AND METHODS: We prospectively evaluated voided urine and/or barbotage specimens from 291 patients a mean of 65.2 years old. All voided urine samples were evaluated by quick staining and standard cytology, the BTA stat 1-step qualitative assay (which detects a bladder tumor associated antigen) and the NMP22 test (which detects a nuclear mitotic apparatus protein). In addition, barbotage specimens were evaluated by QUANTICYT computer assisted dual parameter image analysis. All patients underwent subsequent cystoscopy and biopsy evaluation of any suspicious lesion. Sensitivity, specificity, and the predictive value of positive and negative results were determined in correlation with endoscopic and histological findings.
RESULTS: In 91 patients with histologically proved transitional cell carcinoma overall sensitivity was 48, 57, 58, 59 and 59% for the NMP22 test, the BTA stat test, rapid staining cytology of barbotage samples, rapid staining cytology of voided urine specimens and image analysis, respectively. For histological grades 1 to 3 underlying transitional cell carcinoma sensitivity was 17, 61 and 90% for urinary cytology, 48, 58 and 63% for the BTA stat test, and 52, 45 and 50% for the NMP22 test, respectively. Specificity was 100% for cytology, 93% for image analysis, 70% for the NMP22 test and 68% for the BTA stat test.
CONCLUSIONS: Immunological markers are superior to cytological evaluation and image analysis for detecting low grade transitional cell carcinoma but they have low specificity and sensitivity in grade 3 transitional cell carcinoma. Urine bound diagnostic tools cannot replace cystoscopy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9598479

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  30 in total

Review 1.  Current Use and Promise of Urinary Markers for Urothelial Cancer.

Authors:  William Tabayoyong; Ashish M Kamat
Journal:  Curr Urol Rep       Date:  2018-10-17       Impact factor: 3.092

2.  Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation.

Authors:  Haythem Dimashkieh; Daynna J Wolff; T Michael Smith; Patricia M Houser; Paul J Nietert; Jack Yang
Journal:  Cancer Cytopathol       Date:  2013-06-25       Impact factor: 5.284

3.  Diagnostic Utility of the ImmunoCyt/uCyt+ Test in Bladder Cancer.

Authors:  Kirsten L Greene; Anna Berry; Badrinath R Konety
Journal:  Rev Urol       Date:  2006

4.  Urine cytology and adjunct markers for detection and surveillance of bladder cancer.

Authors:  Peggy S Sullivan; Jessica B Chan; Mary R Levin; Jianyu Rao
Journal:  Am J Transl Res       Date:  2010-07-25       Impact factor: 4.060

5.  Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.

Authors:  Murat Lekili; Ercüment Sener; Mehmet Akif Demir; Gökhan Temeltaş; Talha Müezzinoğlu; Coşkun Büyüksu
Journal:  Urol Res       Date:  2003-12-19

6.  Critical evaluation of urinary markers for bladder cancer detection and monitoring.

Authors:  Shahrokh F Shariat; Jose A Karam; Yair Lotan; Pierre I Karakiewizc
Journal:  Rev Urol       Date:  2008

7.  Prospective evaluation of FISH for detecting upper tract urothelial carcinoma in voided urine specimens.

Authors:  Qiubo Yu; Yanan Li; Gang Li; Tinghong Li; Han Zeng; Zhu Yang; Deling Wang
Journal:  Oncol Lett       Date:  2016-05-17       Impact factor: 2.967

8.  [The value of urinary cytology in the diagnosis of high grade urothelial tumors].

Authors:  C Niedworok; V Rembrink; O W Hakenberg; C Börgermann; R Rossi; T Schneider; M Becker; T Szarvas; C von Ostau; A Swoboda; H Rübben; F vom Dorp
Journal:  Urologe A       Date:  2009-09       Impact factor: 0.639

Review 9.  [Non-invasive urinary diagnosis of bladder cancer. What do we know?].

Authors:  I Kausch; A Böhle
Journal:  Urologe A       Date:  2003-04-11       Impact factor: 0.639

10.  [Analyses of the role of immunocytology in the differential diagnosis of patients with asymptomatic microhematuria].

Authors:  B J Schmitz-Dräger; L-A Tirsar; C Schmitz-Dräger; B Beiche; E Bismarck; T Ebert
Journal:  Urologe A       Date:  2008-02       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.